MJJ Biotech
A pioneer in antisense nucleic acid treatments, leveraging advanced research and screening technologies protected by robust patents.
A pioneer in antisense nucleic acid treatments, leveraging advanced research and screening technologies protected by robust patents.
MJJ Biotech is a biotech startup founded in 2019 that specializes in antisense nucleic acid drugs. It boasts advanced blockmir nucleic acid drug research and development capabilities and dosevo nucleic acid drug screening technology, all of which are safeguarded by a comprehensive patent portfolio. The company's slogan, "A pioneer in antisense nucleic acid treatments, leveraging advanced research and screening technologies protected by robust patents," reflects its commitment to innovation and intellectual property protection. In its latest funding round, the company secured a Series A investment on 28 September 2023 from prominent investors including Guangzhou Science City Venture Capital and Knowledge City Venture Capital. MJJ Biotech operates in the biopharma and biotechnology industries, positioning itself as a key player in the development of cutting-edge nucleic acid-based treatments.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 2 | Guangzhou Science City Venture Capital, Knowledge City Venture Capital | 28 Sep 2023 |
| Series A | Unknown | 1 | Guangzhou Science City Venture Capital | 01 Jan 2020 |
| Angel Round | Unknown | 1 | Aoqi Shengjia Technology Partnership | 01 Aug 2019 |
No recent news or press coverage available for MJJ Biotech.
We care about your data, and we'd love to use cookies make your experience better.